Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology firm pioneering "Bicycle" peptide technology, reported its fourth-quarter and full-year 2025 financial results on March 17, 2026.
The company’s financial profile for the year was heavily influenced by the recognition of deferred revenue following the conclusion of major industry collaborations.
Collaboration revenue jumped to $72.6 million for the year, more than doubling the $35.3 million reported in 2024.
This increase was primarily technical, resulting from the accelerated recognition of remaining revenue after Novartis Pharma AG and Bayer Consumer Care AG terminated specific collaboration agreements and target programs.
Research and development (R&D) expenses rose to $240.3 million for the full year, a 39% increase over 2024.
This spending spike was attributed to the continued clinical advancement of zelenectide development and a strategic workforce reduction completed in August 2025, which included one-time severance-related costs.
Despite the higher annual spend, R&D costs in the fourth quarter remained relatively stable at $51.8 million, as the company began to realize efficiencies from its narrower focus on high-priority clinical programs and transitioned away from certain earlier-stage Bicycle TICA® molecules.
Financially, Bicycle Therapeutics maintains one of the more robust balance sheets in the mid-cap biotech sector.
As of December 31, 2025, the company held $628.1 million in cash and cash equivalents.
While this is down from $879.5 million at the end of 2024, the current capital provides a multi-year runway to fund the ongoing development of its proprietary pipeline.
The net loss for the fourth quarter narrowed significantly to $20.2 million, or $0.29 per share, largely due to the timing of collaboration revenue recognition, while the full-year net loss stood at $219 million.
Looking ahead to 2026, the company is focused on the continued clinical execution of its "Bicycle Toxin Conjugates" (BTCs).
The transition out of broader platform collaborations with large pharma partners allows Bicycle to retain more downstream value and control over its core assets.